• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

A new hope for people with visceral leishmaniasis and HIV co-infection

WHO-recommended treatment combination improves outcomes for people affected by both diseases

14 Jun 2022

Viewpoint by
Dr Monique Wasunna, Eastern Africa Regional Director, DNDi 
Dr Kavita Singh, India & South Asia Regional Director, DNDi 

We are delighted to share the news that the World Health Organization (WHO) has released new guidelines for the treatment of visceral leishmaniasis (VL) in people living with HIV – recommending a new combination therapy proven significantly more effective than the previous standard treatment. 

At DNDi we are proud to have mobilized our partnerships to contribute to the evidence evaluated by WHO in developing its new guidance. Our teams and research partners in Eastern Africa and South Asia have been focusing on studies to improve VL outcomes for people living with HIV for over a decade. 

Both diseases affect the immune system, and both are fatal without treatment. When they occur together, treatment of both VL and HIV becomes more challenging – and their joint impact on the immune system can leave patients vulnerable to other life-threatening opportunistic infections such as tuberculosis and malaria. 

In two Phase III clinical trials conducted in Northwest Ethiopia, led by DNDi, and in Bihar, India, led by Médecins Sans Frontières (MSF), participating patients were treated with liposomal amphotericin B (LAmB) alone, or a combination of LAmB with miltefosine. The combination treatment was shown to have an 88% efficacy rate in Ethiopia (compared to 55% for the standard treatment) and a 96% efficacy rate in India (compared to 88% for the standard treatment). 

With concerted efforts by governments to update national treatment guidelines and scale up access to the new regimen, we know that we can make great strides: saving lives and reducing the terrible stigma and social exclusion that people facing both diseases so often experience. 

We are grateful to our many partners and supporters who have accompanied DNDi in fulfilling our commitment to science and innovation for people living with VL and HIV, including MSF, the University of Gondar (Ethiopia), and the Rajendra Memorial Research Institute of Medical Sciences (India). Please join us as we continue our work to develop the simple, effective, all-oral treatments still needed to pave the road to sustainable VL elimination worldwide. 


More information

Press release, 8 June 2022: New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV

Visceral leishmaniasis

Read, watch, share

Loading...
News
8 Aug 2025

Statement from DNDi on Kenya’s elimination of rhodesiense sleeping sickness as a public health problem 

News
5 Aug 2025

ADB and DNDi sign MoU to advance healthcare cooperation on neglected diseases in Asia and the Pacific

Press releases
23 Jul 2025

AN2 Therapeutics and DNDi collaborate on clinical development of promising new oral compound to treat chronic Chagas disease

Publications
15 Jul 2025

DNDi 2024 Annual Report

Healthcare worker attending a training
Press releases
10 Jul 2025

New HIV project in the DRC brings life-saving care closer to people with advanced HIV disease

Woman working in a laboratory
News
10 Jul 2025

LEO Foundation partners with DNDi to develop breakthrough drug discovery model for mycetoma 

Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License